Free Trial

Greenwich LifeSciences (GLSI) Competitors

Greenwich LifeSciences logo
$10.68 +0.13 (+1.23%)
As of 12:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GLSI vs. ZVRA, TYRA, TSHA, OPT, BCYC, KURA, SEPN, ABVX, MAZE, and PRME

Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.

Greenwich LifeSciences vs. Its Competitors

Zevra Therapeutics (NASDAQ:ZVRA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Zevra Therapeutics currently has a consensus price target of $23.71, indicating a potential upside of 98.28%. Greenwich LifeSciences has a consensus price target of $39.00, indicating a potential upside of 265.17%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Zevra Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Greenwich LifeSciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Zevra Therapeutics had 12 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 12 mentions for Zevra Therapeutics and 0 mentions for Greenwich LifeSciences. Zevra Therapeutics' average media sentiment score of 0.73 beat Greenwich LifeSciences' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Zevra Therapeutics Positive
Greenwich LifeSciences Neutral

Greenwich LifeSciences has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -226.78%. Zevra Therapeutics' return on equity of -201.05% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics-226.78% -201.05% -53.55%
Greenwich LifeSciences N/A -450.87%-333.18%

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Zevra Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Greenwich LifeSciences has lower revenue, but higher earnings than Zevra Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zevra Therapeutics$23.61M27.70-$105.51M-$1.90-6.29
Greenwich LifeSciencesN/AN/A-$15.79M-$1.26-8.48

Summary

Zevra Therapeutics beats Greenwich LifeSciences on 11 of the 16 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLSI vs. The Competition

MetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$142.57M$2.97B$5.59B$9.02B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-8.4621.5127.5220.21
Price / SalesN/A256.10414.66171.34
Price / CashN/A41.8337.0657.97
Price / Book56.217.808.095.62
Net Income-$15.79M-$55.05M$3.17B$248.50M
7 Day Performance6.43%5.29%3.48%4.82%
1 Month Performance10.79%3.81%3.69%7.34%
1 Year Performance-32.28%5.58%33.83%21.46%

Greenwich LifeSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLSI
Greenwich LifeSciences
1.4827 of 5 stars
$10.68
+1.2%
$39.00
+265.2%
-32.0%$142.57MN/A-8.463
ZVRA
Zevra Therapeutics
2.7637 of 5 stars
$11.27
+15.7%
$23.14
+105.3%
+111.1%$532.58M$23.61M-5.9320News Coverage
Analyst Forecast
Gap Up
High Trading Volume
TYRA
Tyra Biosciences
1.7697 of 5 stars
$9.61
-3.9%
$30.83
+220.8%
-43.9%$530.90MN/A-5.9020
TSHA
Taysha Gene Therapies
2.6935 of 5 stars
$2.34
-4.5%
$8.20
+250.4%
+13.4%$525.92M$8.33M-6.88180
OPT
Opthea
0.3919 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+71.4%$524.84M$120K0.008Gap Up
BCYC
Bicycle Therapeutics
4.1543 of 5 stars
$7.17
-3.5%
$25.00
+248.7%
-60.7%$514.56M$35.28M-2.28240
KURA
Kura Oncology
4.5448 of 5 stars
$5.68
-3.1%
$24.50
+331.3%
-70.1%$507.33M$53.88M-2.70130
SEPN
Septerna
1.1163 of 5 stars
$10.85
-4.6%
$26.75
+146.5%
N/A$506.63M$1.08M0.00N/ANews Coverage
ABVX
Abivax
2.5643 of 5 stars
$7.95
-0.1%
$31.00
+289.9%
-37.2%$505.10MN/A0.0061Positive News
Gap Up
High Trading Volume
MAZE
Maze Therapeutics
N/A$12.12
+5.4%
$25.67
+111.8%
N/A$503.67M$167.50M0.00121News Coverage
Analyst Forecast
Analyst Revision
PRME
Prime Medicine
4.0646 of 5 stars
$3.80
+22.2%
$10.08
+165.4%
-19.2%$498.92M$3.85M-1.85234Options Volume
High Trading Volume

Related Companies and Tools


This page (NASDAQ:GLSI) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners